Koji Sasaki

171PUBLICATIONS
308CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (171)

|Jul 10, 2026
Germline landscape stratification defines distinct molecular and prognostic groups in therapy related myeloid neoplasms.

|Jun 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

|Apr 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

|Apr 26, 2026
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.

|Apr 24, 2026
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

|Apr 14, 2026
Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.

Jayastu Senapati, Hagop M Kantarjian, Edward Ayoub

Pageof 29

Frequent Collaborators

93 joint publications

Tapan M Kadia

89 joint publications

Naval G Daver

88 joint publications

Nicholas Short

84 joint publications

Hagop M Kantarjian